TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03110653
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
Study: NCT03110653
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
Study: NCT02251717
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT03780478
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
Study: NCT03780478
Drug: Placebo Saline Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection, total volume 2ml
Study: NCT02688088
Drug: Drug Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01842932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
Study: NCT00002839
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01839019
Drug: Placebo for ODM-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose escalation
Study: NCT00803348
Drug: Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
Study: NCT00803348
Drug: Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
Study: NCT05143723
Drug: Gonadotropin-releasing hormone agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: luteal phase support with gonadotropin-releasing hormone agonist
Study: NCT02362945
Drug: Intervention group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
Study: NCT00798317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection placebo.
Study: NCT01930890
Drug: oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study: NCT04021173
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Study: NCT01024491
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: active daily treatment with placebo
Study: NCT00996281
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet.
Study: NCT01794741
Drug: Dymista Nasal Spray
Normalized name: Dymista Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04535713
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study: NCT00902993
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, oral single and multiple dose
Study: NCT00902993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03054350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose
Study: NCT02351687
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00881153
Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02088073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Study: NCT03871348
Drug: SAR441000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral
Study: NCT02345668
Drug: Treatment as Usual (Pharmacological Treatment)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
Study: NCT01468610
Drug: desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-100 mg daily for 8 weeks
Study: NCT01023087
Drug: Non-nephrotoxic antibiotics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be decided by the infectious disease consultant
Study: NCT00390117
Drug: CDKI AT7519
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
Study: NCT00016744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
Study: NCT04060381
Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
Study: NCT03332719
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00196586
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02969590
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic progestin to assess effects on cervical mucus.
Study: NCT02704923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
Study: NCT00171925
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
Study: NCT01943838
Drug: SAR245408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT04381325
Drug: MSB0254 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
Study: NCT03023826
Drug: LY3202626 (R-Fasting)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03023826
Drug: LY3202626 (T1-Fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00182767
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03749096
Drug: Intravenous Immunoglobulins, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulins are fractionated blood products made from pooled human plasma.
Study: NCT03749096
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT01763320
Drug: medical group
Normalized name: ALCOHOL 266.1615 mL in 354.882 mL TOPICAL GEL [Iconic Medical Group Hand Sanitizer - 12oz 12oz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
Study: NCT01127555
Drug: 5-fluorouracil, leucovorin, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
Study: NCT00004142
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
Study: NCT00003136
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02088502
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02387125
Drug: Metronomic CPA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01007071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo
Study: NCT01341301
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02273635
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg excipients coated tablets twice a day orally administered for 24 months
Study: NCT02594098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Study: NCT01591421
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
Study: NCT00000558
Drug: angiotensin-converting enzyme inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00316095
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00330044
Drug: Premetrexed (Alimta)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316952
Drug: Long acting β-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: All dosages of LA propranolol and SA metoprolol
Study: NCT01316952
Drug: Other α1/β-adrenergic antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
Study: NCT01316952
Drug: Short acting Non-selective β-blockers and short acting β1-Selective agents
Normalized name: NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
Study: NCT00300482
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg, daily, 12 weeks
Study: NCT00300482
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily, 12 weeks, see Arm Description for dosage information
Study: NCT00300482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type
Study: NCT00199004
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199004
Drug: Dexamethasone / Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199004
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00048815
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT00671372
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00570934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01287221
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02564861
Drug: DS-1971a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
Study: NCT02564861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching DS-1971a suspension
Study: NCT04334382
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
Study: NCT03924518
Drug: Placebo（Normal saline）
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Study: NCT04575818
Drug: GLPG4059 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG4059 for oral administration
Study: NCT04575818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT04575818
Drug: GLPG4059 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG4059 for oral administration
Study: NCT01113489
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml b.i.d.
Study: NCT00100295
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg capsule taken three times a day
Study: NCT00974285
Drug: Fuzheng 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT00974285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT04218162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01556776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Study: NCT01628367
Drug: Medications
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
Study: NCT02743780
Drug: MGV354 ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02743780
Drug: MGV354 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as placebo comparator
Study: NCT06184841
Drug: HAIC combined with intravenous PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
Study: NCT01342744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tab oral twice a day
Study: NCT01460407
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01460407
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00902421
Drug: Antimuscarinics
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinics for 3 months
Study: NCT00103519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00600041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical infusion manner like experimental arm
Study: NCT00462735
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
Study: NCT00525824
Drug: Rosuvastatin (Crestor)
Normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg and 20 mg
Study: NCT00525824
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg and 80 mg
Study: NCT02242981
Drug: LY2623091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01182974
Drug: dypirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gr PO/PZ/PR/IM
Study: NCT01457677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to RO4995819 oral once daily for 6 weeks
Study: NCT01457677
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral once daily for 6 weeks
Study: NCT01457677
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral once daily for 6 weeks
Study: NCT01457677
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral once daily for 6 weeks
Study: NCT01771432
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
Study: NCT00733057
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline as an add-on drug (200 mg/day)
Study: NCT00733057
Drug: Placebo (200 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00138047
Drug: zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02772796
Drug: SENS-218
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT00536016
Drug: JSM6427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
Study: NCT00045747
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02958202
Drug: BMN 044 IV 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02958202
Drug: BMN 044 IV 9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02958202
Drug: BMN 044 SC 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01539018
Drug: sorafenib plus tegafur-uracil
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
Study: NCT03274427
Drug: Arginine hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Study: NCT06437626
Drug: Mexidol
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/ml IV solution, 250 mg tablets
Study: NCT06437626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV solution, Placebo tablets
Study: NCT02191761
Drug: SM04755
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating Doses
Study: NCT02691403
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04883840
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
Study: NCT04134130
Drug: Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector
Normalized name: Gonal F RFF Pen 900 UNT per 1.5 ML Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
Study: NCT04472676
Drug: LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01615055
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-40 mg fluoxetine po qd for 6 months
Study: NCT04472676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02581397
Drug: Transpulmin suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
Study: NCT00474864
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03824405
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle liquid formulation
Study: NCT00262678
Drug: EN3267
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04233658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x2 capsules / day
Study: NCT04233658
Drug: Cynara Scolymus
Normalized name: Cynara scolymus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x2 capsules / day
Study: NCT01820455
Drug: Soap baths, Lubricating Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap and water baths with lubricating jelly to the nares, once daily for 5 days